Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 1999-07-29 Board/Management Inform…
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
Ad hoc-Service: MorphoSys AG Board_E
Board/Management Information Classification · 99% confidence The document is an 'Ad hoc-Service' press release from MorphoSys AG dated July 29, 1999. The headline explicitly states: 'MORPHOSYS ANNOUNCES CHANGES TO BOARD OF DIRECTORS AND APPOINTS NEW CHAIRMAN'. The text details the appointment of Dr. Gerald Moeller as Non-Executive Chairman and the departure of Dr. Goeran Ando and Alex Korda. This content directly relates to changes in senior management and the board of directors. This matches the definition for Board/Management Information (MANG). The document length (3390 chars) is substantial enough to be the primary announcement, not just a brief RPA.
1999-07-29 English
Ad hoc-Service: MorphoSys AG Board
Board/Management Information Classification · 99% confidence The document is an 'Ad hoc-Service' announcement from MorphoSys AG dated July 29, 1999. The content explicitly details changes in the company's Supervisory Board (Aufsichtsrat), including the appointment of a new chairman (Dr. Gerald Moeller) and the resignation of previous members. This directly corresponds to the definition of 'Board/Management Information' (MANG), which covers announcements of changes in the company's board of directors or senior management.
1999-07-29 German
Ad hoc-Service: MorphoSys AG bfs grant
Capital/Financing Update Classification · 95% confidence The document is an 'Ad hoc-Service' announcement dated May 28, 1999, detailing that MorphoSys AG is receiving a grant (Foerdermittel) of DM 3.365 million from the Bavarian Research Foundation (BFS) for a specific research project. This announcement concerns financing, funding, or capital structure changes related to a specific corporate activity (research grant acquisition). This aligns best with the 'Capital/Financing Update' category (CAP), as it is a significant inflow of funds/support for the company's operations/projects, distinct from standard earnings or regulatory reports. It is not a full financial report (10-K, IR), an earnings release (ER), or a general regulatory filing (RNS), but a specific announcement about corporate funding.
1999-05-28 German
Ad hoc-Service: MorphoSys AG 1.q e
Earnings Release Classification · 99% confidence The document is titled 'MorphoSys Reports First Quarter Financial Results And Reviews Progress' and explicitly states it is announcing 'financial results for the first quarter ended 31 March 1999'. It provides key financial metrics (Revenues, Operating loss, Net loss) and discusses business progress. This content structure aligns perfectly with an Earnings Release (ER), which is the initial announcement of periodical financial results, typically highlighting key figures before a more comprehensive report might follow. It is too detailed for just a Report Publication Announcement (RPA) and is not the comprehensive annual report (10-K) or the comprehensive interim report (IR), but rather the initial release of the quarterly figures. Q1 1999
1999-05-28 English
Ad hoc-Service: MorphoSys AG bfs e
Regulatory Filings Classification · 95% confidence The document is a short press release dated May 28, 1999, announcing that MorphoSys AG received a DM 3.365 million grant from the Bavarian Research Foundation (BFS) to fund a three-year research project. It details the project scope (antibody library construction) and includes quotes from the CSO. This is a specific corporate announcement regarding funding/grants, which aligns best with the 'Capital/Financing Update' category (CAP), as grants are a form of financing/funding received by the company. It is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). Given the nature of receiving a significant grant, CAP is the most appropriate fit.
1999-05-28 English
Ad hoc-Service: MorphoSys AG 1. q99
Earnings Release Classification · 99% confidence The document is titled 'MORPHOSYS VEROEFFENTLICHT DIE ERSTEN QUARTALSZAHLEN 1999' (MorphoSys publishes the first quarterly figures 1999) and explicitly states it is the 'Finanzbericht fuer das 1. Quartal 1999 zum 31. Maerz' (Financial report for the 1st quarter 1999 as of March 31st). It details revenues, operating loss, net loss, and cash position for the first quarter. This content aligns perfectly with the definition of an Interim / Quarterly Report (IR). Although it is an announcement ('Ad hoc Mitteilung'), the core content provided is the summary of the quarterly financial results, making 'IR' a more specific classification than 'ER' (which is usually just highlights) or 'RPA' (which usually just announces the report's availability). Given the detail provided, it functions as the primary release of the quarterly figures. Q1 1999
1999-05-28 German

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.